Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
250 hedge funds and large institutions have $6.65B invested in Apellis Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 67 funds opening new positions, 93 increasing their positions, 65 reducing their positions, and 27 closing their positions.
148% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 27
61% more capital invested
Capital invested by funds: $4.13B → $6.65B (+$2.52B)
43% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 65
18% more funds holding
Funds holding: 211 → 250 (+39)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
2.73% more ownership
Funds ownership: 86.04% → 88.77% (+2.7%)
17% less call options, than puts
Call options by funds: $92M | Put options by funds: $111M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$59.2M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$56M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$55.2M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$37.2M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$31.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$315M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$93.8M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$61M |
| 4 |
State Street
Boston,
Massachusetts
|
-$31.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$20.8M |
APLS Hedge Fund Activity: Q3 2022 in Review
250 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2022, worth a combined $6.65B — up 61% from $4.13B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new APLS positions and 27 closed out — a net gain of 40 holders — while 93 added to existing stakes and 65 trimmed.
The largest buyer was Artal Group, opening a new position worth an estimated $59.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $315M.
- 250 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2022, up from 211 in Q2 2022.
- Funds reported $6.65B of Apellis Pharmaceuticals stock for Q3 2022, up 61% quarter-over-quarter.
- 67 funds opened new Apellis Pharmaceuticals positions in Q3 2022 and 27 closed out, a net change of +40 holders.
- The largest Apellis Pharmaceuticals buyer in Q3 2022 was Artal Group, an estimated $59.2M added.
- The largest Apellis Pharmaceuticals seller in Q3 2022 was T. Rowe Price Associates, an estimated $315M sold.
Based on aggregated 13F filings for Q3 2022.